[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634025":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":18,"centralContacts":22,"locations":29,"responsibleParty":50,"collaborators":10,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":10,"enrollmentInfo":62,"targetDuration":10,"studyType":65,"phases":10,"briefSummary":66,"conditions":67,"keywords":72,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"University of Zurich","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with an acute ischemic stroke of the ICA, MCA or both with successful revascularization",null,"* Male and female subjects \\>18 years old.\n* Acute ischemic stroke related to a new occlusion of the internal carotid artery, middle cerebral artery (M1- and\u002For M2-segment), or both.\n* Eligibility and performance of endovascular thrombectomy.\n* Achievement of successful recanalization, defined as mTICI score ≥2b\n* Written informed consent of the patient or when the patient is not able to participate in the consenting procedure, the written authorization of an independent doctor not involved in the research project is requested to safeguard the interests of the patients (in that case, post hoc written informed consent of the patient or next of kin had to be obtained). Foreign speaking patients should be included by a person with sufficient German language proficiency to act as a translator.",[13],"Other: No planned intervention",[15],{"type":6,"name":16,"description":16,"armGroupLabels":17,"otherNames":10},"No planned intervention",[9],[19],{"name":20,"affiliation":5,"role":21},"Jorn Fierstra, Prof Dr. med., PhD","PRINCIPAL_INVESTIGATOR",[23],{"name":24,"role":25,"phone":26,"phoneExt":27,"email":28},"Meltem Gönel, Dr. med.","CONTACT","43 253 90 19","0041","meltem.goenel@usz.ch",[30],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Zurich University Hospital","RECRUITING","Zurich","Canton of Zurich","8006","Switzerland","CH",{"type":39,"coordinates":40},"Point",[41,42],8.55,47.36667,{"lat":42,"lon":41},[45,47],{"name":24,"role":25,"phone":26,"phoneExt":46,"email":28},"+41",{"name":48,"role":25,"phone":10,"phoneExt":10,"email":49},"Jacopo Bellomo, Dr.","jacopo.bellomo@usz.ch",{"type":21,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Jorn Fierstra","Prof Dr. med., PhD","100634025","investigation-of-brain-blood-flow-changes-in-acute-ischemic-stroke-patients-after-successful-endovascular-thrombectomy-100634025",false,"NCT07534319","Investigation of Brain Blood Flow Changes in Acute Ischemic Stroke Patients After Successful Endovascular Thrombectomy","RESTORE-AIS","Inclusion Criteria:\n\n* Male and female subjects \\>18 years old.\n* Acute ischemic stroke related to a new occlusion of the internal carotid artery, middle cerebral artery (M1- and\u002For M2-segment), or both.\n* Eligibility and performance of endovascular thrombectomy.\n* Achievement of successful recanalization, defined as mTICI score ≥2b\n* Written informed consent of the patient or when the patient is not able to participate in the consenting procedure, the written authorization of a family member. Foreign speaking patients should be included by a person with sufficient German language proficiency to act as a translator.\n\nExclusion Criteria:\n\n* Documented evidence or a confirmed willingness of the patient not to participate in any scientific study.\n* Standard contraindications for MRI, such as pacemaker, metallic prothesis, glaucoma, metallic tattoo dyes, verbal confirmed pregnancy. Unwilling or unable to cooperate with breathing manoeuvres.\n* Major cardiopulmonary diseases, such as severe uncontrolled asthma bronchiale, severe chronic obstructive lung disease (i.e., GOLD stage ≥III), diffuse interstitial lung disease, pulmonary embolism, acute\u002Fsubacute myocardial infarction, or severe heart failure (i.e., NYHA class ≥III).\n* Symptomatic increased intracranial pressure.\n* Presence of intracranial haemorrhage type ≥2 according to the Heidelberg classification.\n* New onset of seizure.","ALL","18 Years",{"count":63,"type":64},100,"ESTIMATED","OBSERVATIONAL","Introduction:\n\nEndovascular thrombectomy (EVT) is an effective treatment strategy to mitigate the ischemic tissue damage caused by the acute cerebral large-vessel occlusion. However, in clinical practice, nearly half of the patients do not experience adequate neurological improvement despite successful recanalization - a phenomenon termed reperfusion failure or clinically ineffective reperfusion. Given the clinical relevance of this phenomenon and the absence of a standardized imaging diagnostic method to identify it, our project aims to explore the potential role of blood oxygenation-level dependent cerebrovascular reactivity (BOLD-CVR) as novel imaging biomarker for studying reperfusion failure.\n\nStudy population:\n\nAdult patients with acute ischemic stroke of the ICA, MCA or with tandem occlusion who have undergone a successful recanalization, described as mTICI score ≥2b.\n\nObjective(s):\n\nPrimary objective: to longitudinally observe blood flow changes derived from BOLD-CVR imaging following successful endovascular thrombectomy in patients with large-vessel occlusion acute ischemic stroke (LVO-AIS) during the early post-treatment phase and assess their association with clinical outcome 90 days post-EVT.\n\nSecondary objective: to compare BOLD-CVR findings with those obtained from the clinical standard dynamic susceptibility contrast (DSC) MR perfusion imaging acquired in the same examination session as well as other imaging techniques included in the standard post-treatment imaging protocol at our institution.\n\nOutcomes:\n\nClinical outcomes:\n\n* 90-day functional outcome.\n* Functional outcome at hospital discharge.\n* Neurological deterioration during hospitalization.\n* Radiologically confirmed haemorrhagic transformation within the reperfused tissue.\n* Radiologically confirmed infarct lesion progression within the reperfused tissue.\n* Additionally, DSC MR perfusion imaging parameters and other standard hemodynamic imaging parameters will be considered as imaging outcomes\n\nStudy design:\n\nSingle-center prospective observational cohort study\n\nMeasurements and procedures:\n\nIncluded patients will undergo a total of 3 BOLD-CVR examinations: 72 hours, 7 days, and 90 days after EVT. Participation in the final examination will mark the end of the subject's involvement in the study. Clinical outcomes will be prospectively collected as per established institutional patient management protocols: during hospitalization, at discharge, and at the cerebrovascular outpatient clinic at 3 months.\n\nNumber of Participants:\n\nTarget sample size: 100 patients\n\nGiven the observational study design and exploratory nature of this project, no sample size calculation can be performed. The provided target sample size (N = 100) has been estimated considering the inclusion of as many consecutive subjects as possible.\n\nStudy period: 2.5 years The investigators aim to enroll a target sample size of 100 patients over a period of 2.5 years. This translates to an inclusion of 3-4 patients per month, with the last three months allocated for the follow-up of the last included patients.\n\nStudy Centre:\n\nClinical Neuroscience Center, Department of Neurosurgery, University Hospital Zurich\n\nStatistical Considerations:\n\nThe association between BOLD-CVR findings and clinical outcomes will be investigated using regression analyses.",[68,69,70,71],"Acute Cerebrovascular Accident","Thrombectomy","Cerebral Revascularization","No Reflow Phenomenon",[73,69,74,70,71,75,76],"Acute Ischemic Stroke","Reperfusion Failure","BOLD-CVR","Advanced Haemodynamic Imaging","2026-04-09",{"date":79,"type":80},"2026-04-16","ACTUAL",{"date":82,"type":80},"2025-06-01",{"date":84,"type":64},"2027-12-01",{"name":5,"class":6},1]